Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma

IntroductionChimeric antigen receptor (CAR) T-cell therapy (CAR T therapy) is a treatment option for patients with relapsed or refractory multiple myeloma that has led to unprecedented treatment outcomes. Among CAR T therapies available, ciltacabtagene autoleucel (cilta-cel) is a good candidate for...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Doris K. Hansen, Binod Dhakal, Mehdi Hamadani, David Dingli, Tania Jain, Carol Ann Huff, Murali Janakiram, Yi-Hsuan Liu, Kevin C. De Braganca, Nicole Lodowski, Jennifer Sander, Peter Okorozo, Lindsay McFarland, Matthew Perciavalle, Stephen Huo, Zaina P. Qureshi, Krina K. Patel
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2024-06-01
Schriftenreihe:	Frontiers in Immunology
Schlagworte:	ciltacabtagene autoleucel cilta-cel outpatient car t therapy CAR T-cell relapsed or refractory multiple myeloma
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1405452/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!